MRKR · NASDAQ · Biotechnology

Marker Therapeutics

Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.

$1.37
After-hours close+0.02 (+1.75%)
At close$1.35(−7.53%)

Breakdown13F · Form 4

Institutions 23.81%Insiders

Shares outstanding 16.67M · Float 13.50M · 81.0% free float

Insiders — no current Form 4 position.

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
New Enterprise Associates 16, L.P.1.67M9.90%13DNov 17, 2025
Nea Management Company, LLC1.63M9.75%13FAug 14, 2026
Alyeska Investment Group, L.P.1.28M9.90%13GNov 14, 2025
Blue Owl Capital Holdings LP554.3K3.32%13FAug 11, 2026
Vanguard Capital Management LLC426.2K2.56%13FAug 13, 2026

Institutions13F, as of Jun 30, 2026

35 holders · 3.97M shares · 4 new positions · 10 increased · 7 reduced · 5 closed

HolderShares% outstandingChg q/qFiled
Nea Management Company, LLC1.63M9.75%0Aug 14, 2026
Blue Owl Capital Holdings LP554.3K3.32%0Aug 11, 2026
Vanguard Capital Management LLC426.2K2.56%+36.9KAug 13, 2026
Aisling Capital Management LP325.4K1.95%0Aug 13, 2026
Renaissance Technologies LLC249.4K1.50%+74.1KAug 13, 2026
Geode Capital Management, LLC139.8K0.84%−21.1KAug 12, 2026
Advisor Group Holdings, Inc.112.6K0.68%+19.5KAug 14, 2026
Vanguard Fiduciary Trust Co87.3K0.52%0Aug 13, 2026

Beneficial owners13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Blue Owl Capital Holdings LP9.99%1.13M13GMay 15, 2025
New Enterprise Associates 16, L.P.incl. Forest Baskett, Carmen Chang +7 more9.90%1.67M13DNov 17, 2025
Alyeska Investment Group, L.P.9.90%1.28M13GNov 14, 2025

InsidersForm 4

No current Form 4 position on record.

15 ten-percent owners hold 13.17M shares by Form 4, outside the officers-and-directors figure above · 21 people have not refiled in the last 18 months (1.69M shares), so they are not in the figure above

Latest trades

No open-market trades in the last 12 months.

CongressHouse and Senate disclosures

Not reported.